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“Jim Watson and I have probably made a most important discovery. We have built a model for 
the structure of de-oxy-ribose-nucleic-acid (read it carefully) called D.N.A. for short (…) Our 
structure is very beautiful. D.N.A. can be thought of roughly as a very long chain with flat bits 
sticking out. The flat bits are called the “bases” (…) It is like a code. If you are given one set of 
letters you can write down the others. Now we believe that the D.N.A. is a code. That is, the 
order of the bases (the letters) makes one gene different from another gene (…) You can now 
see how Nature makes copies of the genes. (…) In other words we think we have found the 
basic copying mechanism by which life comes from life. The beauty of our model is that the 
shape of it is such that only these pairs can go together, though they could pair up in other ways 
if they were floating about freely (…) Read this carefully so that you understand it.” 
Francis Crick’s Letter to Son (1953) 
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 Abstract 
Renal cell carcinoma (RCC) denotes a common group of chemoresistant cancers 
derived from the renal epithelium. RCC accounts for over 90% of all the cancers in the 
kidney and includes over 10 histological and molecular subtypes. Clear cell renal cell 
carcinoma (ccRCC) is the most common RCC subtype and accounts for most cancer-
related deaths. Importantly, complete surgical resection remains the only curative treatment 
for RCC, for it is of critical importance to develop new therapeutic, less invasive strategies 
as curative intents for this disease. 
Compelling evidence exists over the influence of obesity on cancer development. 
Excess adipose tissue (AT) accrual is a well-established factor for cancer incidence. 
Notably, RCC is among the cancers for which this effect is more evident. However, RCC 
obese patients at diagnosis experience longer survival than non-obese patients, a 
phenomenon termed “obesity paradox”. Notwithstanding, the influence of the adipose depot 
in RCC, and particularly, in ccRCC is yet largely unexplored. 
This project focused on providing a better understanding of the adipose 
tissue/ccRCC interface and unveil potential mechanisms through which adipose tissue 
exerts its influence on ccRCC. Following on this premise, the work herein developed aims 
to contribute to the current state of knowledge over the bidirectional crosstalk between 
adipose tissue and cancer by: i) exploring the intrinsic differences between adjacent tumour 
and distant adipose depots; ii) addressing the influence of AT secreted factors on hypoxia, 
inflammatory-, epithelial to mesenchymal transition- (EMT) and stem-related gene 
expression in ccRCC cell lines; and iii) evidencing the role of adipose depot-derived soluble 
factors on established hallmarks of cancer, namely, proliferation and apoptosis of 786-O 
and Caki-1 cells. The resulting data suggest that, in fact, both perirenal (PrAT) and 
subcutaneous (ScAT) adipose depots exert an influence over clear cell renal cell carcinoma 
primary tumours, by increasing the expression of genes that contribute to progression and 
development of ccRCC and decreasing tumour viability. However, these counterintuitive 
data could not be observed in metastatic ccRCC Caki-1 cell line. 
In conclusion, this work provides a better understanding of the influence of site-
specific adipose depots for ccRCC and, importantly, conveys promising data to educate 
future research and expand the knowledge over the AT/cancer interface, and ultimately, 
giving prospective future approaches for the development of novel therapeutic targets to 
impact not only ccRCC itself, but the surrounding microenvironment, in particular, the 
adipose depot. 
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Resumo 
O carcinoma de células renais (CCR) engloba um grupo de neoplasias 
quimioresistentes derivadas do epitélio renal. Mais de 90% dos cancros renais em adultos 
são CCR, que pode ser subdividido em 10 subtipos histológicos e moleculares. Destes, o 
CCR de células claras (CCRcc) é o mais comum e com maior mortalidade associada. 
Presentemente, a resecção cirúrgica completa é a única abordagem terapêutica disponível 
para pacientes com este cancro, relevando-se a importância do desenvolvimento de novas 
terapias e estratégias cirúrgicas menos invasivas para o seu tratamento. 
Atualmente é aceite que a obesidade influencia o desenvolvimento de cancro. A 
acumulação excessiva de tecido adiposo (TA) está estabelecida como sendo um fator 
relevante na incidência desta doença, sendo o CCR um dos tipos em que este efeito é mais 
evidente. No entanto, em pacientes obesos diagnosticados com CCR observa-se uma taxa 
de sobrevivência superior comparativamente a pacientes não obesos, instituindo-se o 
“paradoxo da obesidade”. Contudo, a influência dos depósitos de TA sobre o CCR, e sobre 
o CCRcc em particular, é uma área de estudo pouco desenvolvida. 
O presente projeto focou-se na análise da interface TA/CCRcc e investigação dos 
potenciais mecanismos pelos quais o TA exerce influência sobre o CCRcc. Seguindo estas 
premissas, o trabalho desenvolvido no âmbito deste projeto teve como objetivo contribuir 
para o estado atual do conhecimento sobre a interação bidirecional do TA e o cancro 
através: i) do estudo das diferenças intrínsecas entre depósitos de TA adjacentes/distantes 
de tumores; ii) da análise da influência de fatores secretados pelo TA na expressão de 
genes em linhas celulares de CCRcc, genes esses relacionados com hipoxia, inflamação, 
transição epitelial-mesenquimal (TEM) e estaminalidade; e iii) do estudo do papel de 
fatores solúveis derivados de depósitos de TA sobre características do cancro bem 
estabelecidas, nomeadamente, sobre a proliferação e apoptose de células 786-O e Caki-
1. Os resultados reunidos nesta tese sugerem que tanto o TA perirrenal (TAPr) como o TA 
subcutâneo (TASc) exercem influência sobre tumores primários de CCRcc, através, por 
um lado, do aumento da expressão de genes que contribuem para o aumento da 
progressão e desenvolvimento do CCRcc e, por outro, da diminuição da viabilidade 
tumoral. No entanto, estas observações contraditórias não foram encontradas em Caki-1, 
uma linha celular metastática de CCRcc. 
Em suma, o trabalho desenvolvido permite uma melhor compreensão da influência 
de depósitos de TA encontrados em locais específicos sobre o CCRcc. Adicionalmente, os 
dados reunidos neste projeto acrescentam ao estado atual do conhecimento, podendo 
sustentar linhas de investigações posteriores focadas na interface TA/cancro. Ultimamente, 
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os resultados do trabalho aqui descrito podem incitar abordagens inovadoras para o 
desenvolvimento de terapêuticas não só focadas no CCRcc em si, mas também no 
microambiente tumoral e no TA em particular. 
Palavras-chave: obesidade, tecido adiposo, carcinoma de células renais de células 
claras, microambiente tumoral.  
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INTRODUCTION 
 
 
RENAL CELL CARCINOMA - A METABOLIC DISEASE 
 
Overview 
Renal cell carcinoma (RCC) is the 13th cause of cancer-related death and one of the 
ten most diagnosed cancers  worldwide, accounting for over 300 000 new cases and 
140 000 deaths every year (Figure 1)1,2. 
 
Figure 1 | Estimated global renal cell carcinoma cancer incidence. From Hsieh et al. Nat. Rev. Dis. Primers 20173. 
Nearly one third of all RCC patients have disseminated metastasis at presentation 
and about half of the patients eventually succumb to the disease4. Importantly, RCC 
denotes not a single disease but a common group of chemoresistant cancers that originate 
from the renal parenchyma and include a spectrum of distinguishable histopathological 
subtypes with distinct molecular profiles, clinical outcomes and treatment responses. Clear 
cell renal cell carcinoma (ccRCC) is the most common and aggressive subtype of RCC and 
is characterized by the presence of glycogen- and lipid-laden cells, implicating several 
alterations in ccRCC development, including fatty acid and glucose metabolic 
dysfunctions3,5-7. 
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Recent exome sequencing studies have highlighted the increased intra-tumour8,9 
and inter-tumour5 heterogeneity found in ccRCC patients, leading to an intricate complex of 
clinical outcomes. Even though relative survival rates have been improved in the past few 
years, a global increase of RCC incidence has been reported. In general, the use of non-
invasive radiological techniques has contributed to this finding. Furthermore, increments in 
global excess body weight, hypertension and cigarette smoking are critical to further 
increase RCC prevalence2. Staging of RCC reflects local invasiveness, lymph node 
involvement and metastases assessment and is mainly accomplished with CT analysis 
(Figure 2)10.  
 
Figure 2 | Renal cell carcinoma staging. Tumour staging is mainly accomplished through computed tomography and reflects 
local invasiveness, lymph node involvement and metastases. Stages I and II are mainly confined to the kidney and surgical 
procedures remain the main curative treatment for these patients. Stage III reflects tumours enclosed within Gerota’s fascia 
limits. In turn, stage IV RCC reflects distant metastases and treatment options mainly focus on systemic treatments, including 
Sunitinib, Sorafenib, Bevacizumab and Everolimus. From Hsieh et al. Nat. Rev. Dis. Primers 20173. 
For patients with surgically resectable ccRCC, the standard procedure remains 
partial or radical nephrectomy with curative intent. However, approximately 30% of patients 
with ccRCC will eventually develop metastasis, which require systemic treatment with 
targeted agents and/or immune checkpoint inhibitors. Complete surgical resection remains, 
however, the only curative treatment for RCC3,11. 
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Mechanistic Insights - Genetic Basis and Pathways 
Dysregulated metabolism is a hallmark of cancer. Tumours reprogram metabolic 
statuses to obtain sufficient energy and biosynthetic building blocks to sustain malignant 
cell proliferation12. Genetically, loss of the short arm of chromosome 3 (3p) is a central 
feature in ccRCC occurring in over 90% of patients. The von Hippel-Lindau tumour 
suppressor gene (VHL) is located on chromosome 3p25 and its biallelic loss through 3p 
loss and concurrent VHL somatic mutation, promoter hypermethylation or deletion is 
considered the defining primary event in this type of cancer5,6,13. Recent whole genome 
sequencing studies highlighted this as the key driver event in ccRCC tumorigenesis14. The 
VHL protein is part of an E3 ubiquitin ligase complex which recognizes, binds and targets 
hypoxia inducible factors (HIFs), in an oxygen-dependent manner, for proteasomal 
degradation. VHL loss-of-function leads to an aberrant accumulation of HIF proteins, that 
become constitutively stabilized in the early carcinogenic process, and direct transcriptional 
programs that promote cellular proliferation, angiogenesis and modulate intracellular 
metabolic processes (Figure 3)15,16. 
 
Figure 3 | VHL loss-of-function in renal cell carcinoma. VHL inactivation is the most frequent genetic manifestation in clear 
cell renal cell carcinoma. In the absence of VHL, HIF transcriptional targets expression increases leading to changes in cellular 
metabolism. HIF transcriptional targets include VEGF, FGF and HGF increasing angiogenesis and cell growth. HGF signalling 
through MET and tumour promoting mutations enhance PI3K/AKT/mTOR activity. Both VHL-HIF and PI3K/AKT/mTOR 
signalling pathways are intrinsically associated with metabolic regulation and constitute the underlying evidence that RCC is 
essentially a metabolic disease. Adapted from Hsieh et al. Nat. Rev. Dis. Primers 20173. 
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Loss of Chromosome 3p  
Large-scale cancer genomic sequencing projects have identified recurrent 
mutations in tumour suppressor genes other than VHL involved in chromatin and/or histone 
modifications, including PBRM1, BAP1 and SETD2, making clear the role of the altered 
epigenetic control of gene expression to the ccRCC carcinogenic processes17.  
The complex interplay between genetics and epigenetics in RCC may be illustrated 
by the role PBRM1 has in ccRCC pathogenesis. PBRM1 is part of the SWI/SNF chromatin-
remodelling complex. In ccRCC, this gene functions as a tumour suppressor gene, and its 
inactivation is associated with dysregulated DNA repair, proliferation and differentiation18. 
Even though the mechanisms by which PBRM1 mutations contribute to RCC remain 
elusive, the regulation of genes that encode proteins essential to proliferation (e.g. p21) and 
cell-adhesion/cell-signalling (e.g. E-cadherin) are thought to play a role in the pro-oncogenic 
effect that the ablation of this gene has in ccRCC carcinogenesis19. In addition, loss of this 
chromatin remodelling factor rescues deficient VHL-mediated DNA damage and replication 
stress, contributing to cellular fitness and promoting proliferation20. In concordance, PBRM1 
has been implicated on the limitation of HIF and STAT3 transcription outputs to over-amplify 
upon VHL loss, suggesting PBRM1 inactivation as the second oncogenic driver in ccRCC21. 
BAP1 encodes a nuclear deubiquitinase, which is inactivated in 15% of ccRCC 
patients, and forms a multiprotein complex with BRCA1 and BARD1, regulating multiple 
cellular pathways including DNA damage, cell cycle and cell proliferation processes22,23. 
Acquisition of BAP1 mutations have been associated with high tumour grades and 
mTORC1 activation, further implicating BAP1 in onco-promoting processes, including EMT, 
growth sustainment and survival22,24. Recently, BAP1 was associated to increase ferroptotic 
cell death-resistance in RCC cell lines de-repressing SLC7A11, a transporter of 
extracellular cystine, enabling the continuous uptake of cystine and GSH synthesis, 
promoting tumour development25. 
SETD2 encodes a histone methyltransferase that is associated with open 
heterochromatin and decreased CpG methylation. Therefore, SETD2 mutations alter the 
expression and functional structure of a myriad of genes by directly repressing gene 
expression or influencing the spliceosome machinery and impacting splice-variants 
expression. SETD2 loss-of-function impairs an efficient gene transcription and has been 
associated with defects on DNA break repair mechanisms and increased genomic 
instability, ultimately, driving malignant cell transformation19,26,27. 
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Notably, four of the most commonly mutated genes in RCC (VHL, PBRM1, BAP1 
and SETD2) are located in chromosome 3p (Figure 4). Allelic loss of 3p is a nearly universal 
event in RCC, and therefore, results in haploinsufficiency for four of the tumour suppressor 
genes are usually related to RCC aggressiveness5,28. 
 
Figure 4 | Renal cell carcinoma is a disease of 3p loss. Four of the most commonly mutated genes in RCC are located 
within the short arm of chromosome 3p. 3p loss is a nearly universal event in the development of RCC. Loss of VHL, PBRM1, 
SETD2 and BAP1 through 3p loss is a common event in RCC. Adapted from Hakimi et al. Nat. Genet. 201328. 
 
Related Signalling Pathways 
Recurrently tumour promoting mutations found in ccRCC also include genes in 
PI3K-AKT-mTOR signalling and p53-related pathways, leading to a series of dysregulated 
cell functions, including apoptosis, cell survival, angiogenesis, cell-cycle regulation, among 
others (Figure 3)3,5,6. In addition, frequently epigenetic mechanisms in ccRCC contribute 
for mTOR increased activity that may lead to increased expression of c-MET and BCL2 
transcripts as well as the inhibition of PTEN. 
Clear cell renal cell carcinoma is further aggravated by altered epigenetic regulation 
on WNT-β-catenin and TGFβ signalling pathways (Figure 5).  
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Figure 5 | Pathways beyond VHL-HIF. WNT signalling is increased through epigenetic deregulation of WNT antagonists. 
These include DKK1, DKK2 and DKK3, which bind to WNT receptors, impairing signalling; and SFRP1,SFRP2 and WIF1 
which directly bind WNT, preventing the bind of WNT to its receptors. In addition, promoter methylation of APC, a component 
of the β-catenin destruction complex, enables β-catenin accumulation and, consecutively, upregulation of its ocogenic target 
genes. Frequent mutations in FBN2 increase TGFβ signalling, further increasing the transcription of tumour promoting genes, 
including epithelial to mesenchymal transcription factors. From Joosten et al. Nat. Rev. Urol. 201817. 
In the absence of WNT binding to its receptor complex, β-catenin is phosphorylated and 
targeted for degradation. However, binding of WNT to its receptor complex leads to 
accumulation and translocation of β-catenin to the nucleus where it associates with DNA-
binding transcription factors of the TCF/LEF family, promoting transcription of target genes 
such as cyclin D1 (CCND1) and c-MYC. In RCC, promoter methylation of the genes 
encoding WNT antagonists and APC result in loss of negative regulation of WNT signalling 
and lead to the accumulation of β-catenin and its downstream targets. Additionally, in VHL-
deficient ccRCC patients, β-catenin can be targeted for degradation. However, this process 
is often impaired owing to promoter methylation and consequent inactivation of WNT 
pathway inhibitors. Notably, β-catenin has also an extremely important role in maintaining 
cell-cell adhesion by binding to the cytoplasmic domain of E-cadherin, and thus preventing 
its proteasomal degradation, contributing to the maintenance of an epithelial phenotype. 
Promoter methylation of CDH1, which encodes E-cadherin, or reduced expression through 
a HIF1α-dependent manner in RCC results in β-catenin availability and ultimately, to 
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increased transcription of its target genes, which include EMT transcription factors (e.g. 
TWIST, SNAI1, SNAI2, and ZEB1), which further repress E-cadherin expression in RCC. 
Importantly, TGFβ signalling triggers the activation of SMAD proteins that directly stimulate 
the expression of the above mentioned EMT transcription factors. In addition, TGFβ 
signalling further enhances mTOR activity, contributing to ccRCC pathogenesis, via PI3K 
and AKT activation. In RCC, promoter methylation of FBN2, a microfibrillar component of 
the ECM that sequesters TGFβ, leads to release of TGFβ from the ECM and consequent 
downstream signalling, further contributing to RCC progression. 
 
Tumour Microenvironment 
The tumour microenvironment (TME) is composed of an intricate milieu of non-
transformed cells and acellular components that include immune cells, fibroblasts, stromal, 
epithelial, endothelial, fat and cancer stem cells, as well as the surrounding ECM 
constituents and the inflammatory mediators that these cells secrete. Elements of the TME 
can interact with tumour cells directly or through paracrine factors that contribute to the 
development, progression and therapy resistance in RCC (Figure 6)12,17,29,30. 
 
Figure 6 | Tumour microenvironment. Tumour cells are surrounded by a myriad of cellular and non-cellular components 
that constitute its microenvironment. These components include endothelial cells of the vascular and lymphatic systems, 
fibroblasts, a complex of immune cells, myeloyd-derived supressor cells (MDSC) mesenchymal stem cells (MSC), adipocytes 
and preadipocytes, and extracellular matrix (ECM) components. Cancer cells are capable of modulating its environment in 
order to initiate metastases and/or promote its growth. 
                                                                                                                                                                            FCUP 
                 The Interplay Between Adipose Tissue and Renal Cell Carcinoma: Decoding the Obesity Paradox 
 
23 
 
 
Immune Landscape 
Tumour cells are able to develop immunosuppressive mechanisms that ultimately 
enable tumour progression31. Immune cells infiltrate the TME and create a niche that is 
capable of modulating nearly every aspect of tumour development. CD4+ and CD8+ T cells 
target antigenic tumour cells to prevent cancer cell growth32. However, tumour cells often 
evade host anti-tumour response by reducing its immunogenicity and activating 
immunosuppressive and/or immunoevasive pathways, decreasing gene transcription of 
genes that encode tumour-associated antigens, HLAs and constituents of the antigen 
processing and presentation machinery, which render cells invisible to CD8+ cytotoxic T 
lymphocytes. Furthermore, upregulation of immunosuppressive molecules, such as 
programmed cell death 1 ligand 1 (PDL1), IL-6, IL-10, TGFβ and VEGF, render cancer cells 
immune resistance17,33. These factors recruit immunosuppressive myeloid-derived 
suppressor cells (MDSCs) to the tumour which, in turn, further represses antitumour 
responses and recruits and/or promote differentiation of cells in tumour-associated 
macrophages (TAMs), regulatory T (Tregs) cells, as well as other immunosuppressive cells17. 
In fact, short-lived patients with ccRCC have extremely high levels of T helper 2 cells and 
Tregs infiltration34,35. 
 
Metabolic Landscape 
Alterations in cellular metabolism has now been widely considered as a hallmark of 
cancer and provide a route for cancer progression and development. Clear cell renal cell 
carcinoma cells are glycogen- and lipid-laden, and therefore, possess dysregulated fatty 
acid and glucose metabolic processes that ultimately, may be representative of ccRCC 
aggressiveness7. VHL inactivation is a central event in ccRCC, either caused by gene 
deletion, mutation and/or silencing via promoter methylation, therefore leading to HIF 
accumulation and consequent HIFα metabolic rearrangements, including glycolysis, fatty 
acid synthesis and glycogen synthesis modifications36.  In fact, recurrent mutations in 
ccRCC are associated with genes that are related to the dysregulation of at least one 
metabolic pathway that is mediated by oxygen, iron, energy or nutrient sensing, further 
supporting the view of ccRCC as a metabolic disease15. A metabolic shift towards increased 
dependence on the pentose phosphate shunt, decreased activities of AMPK and the Krebs 
cycle, increased glutamine transport and higher fatty acid production has already been 
demonstrated to correlate with disease aggressiveness. This poor ccRCC prognosis 
resembles the Warburg metabolic phenotype5,28,36. Therefore, it is somehow expected that 
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obesity is closely associated with ccRCC development and progression, given that ccRCC 
is fundamentally a metabolic disease15. 
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ADIPOSE TISSUE 
Adipose tissue (AT) is increasingly being recognized as a crucial organ that 
contributes to human health processes, through both systemic and local-specific 
functions37. This organ has gained increased interest for its potential in regulating body 
energy expenditure, impacting obesity as a current global epidemic. Obesity stems from the 
imbalance between energy intake and expenditure. If energy consumption constantly 
exceeds energy expenditure, the surplus of energy is stored in adipocytes and adipose 
mass is expanded. This process is particularly important since obesity is associated with an 
intricate array of diseases including type 2 diabetes, cardiovascular diseases, insulin 
resistance and several types of cancer38-40. 
 
Functional Characterization and Adipose Identity 
AT is a critical organ in regulating energy homeostasis composed mainly of 
adipocytes. However, several other cell types can be found within this tissue, including 
vascular endothelial cells, neurons, preadipocytes, fibroblasts and a myriad of immune 
cells. The crosstalk among these different cell types modulates adipose tissue activity on a 
depot and/or type-specific manner41. 
Mammalian adipose tissue can be broadly divided into two functionally distinct 
classes of fat, white (WAT) and brown (BAT), depending on whether this depot is mainly 
composed of white or brown adipocytes, respectively (Figure 7). 
 
Figure 7 | Adipocytes have distinct phenotypic features. Adipocytes are broadly divided into three classes: brown, beige 
and white adipocytes that have distinct functional and morphological characteristics. Brown adipocytes are usually smaller 
than white and beige fat cells and possess numerous lipid droplets and numerous UCP1-expression mitochondria. These 
cells main function resorts in their adaptive thermogenic capacity that is highly dependent on UCP1. White adipocytes mainly 
function as an energy storage cell and possess a large unilocular lipid droplet that occupies nearly all the space within the 
cell. In turn, beige adipocytes are thought to emerge in white adipose depots through transdifferentiation or de novo 
differentiation from preadipocytes and upon stimulation (e.g. cold or β-adrenergic stimuli) present similar phenotypic traits to 
brown adipocytes. From Sanchez-Gurmaches et al. Trends Cell Biol. 201642. 
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Whereas WAT is mainly responsible for the storage and release of energy in 
response to systemic demands, BAT contributes to whole energy body expenditure via 
thermogenic processes, which has set the attention towards the modulation of the adipose 
depot to promote weight loss43-45. 
 
White Adipose Tissue 
White adipocytes are the predominant type of adipocyte and contain large unilocular 
lipid droplets and a low mitochondrial content. These cells are important regulators of 
energy homeostasis and are responsible for the storage of fuel and release of a variety of 
adipokines, including leptin and adiponectin that regulate insulin sensitivity, lipid metabolic 
processes and satiety. WAT is distributed throughout the human body in subcutaneous and 
visceral depots and can both increase in size (hypertrophy) or number (hyperplasia), and 
its expansion is a physiological process critical to the protection of other organs from 
lipotoxicity42,46. However, increased adiposity might lead to an ectopic accumulation of 
triglycerides and underlying metabolic syndrome, which includes impaired glucose 
metabolism and insulin resistance47. Importantly, the overall distribution of WAT has 
profound effects on human health. Excess visceral fat is highly correlated with development 
of metabolic disease. However, increased subcutaneous mass has been associated with 
improved glucose tolerance48. 
 
Brown Adipose Tissue 
Brown adipocytes are enriched in uncoupled protein 1 (UCP1) mitochondria and 
possess small multilocular lipid droplets, mainly contributing to thermogenic processes. 
These cells burn substrates, including glucose and fatty acids, consuming energy by 
dissipating heat through a process known as adaptive thermogenesis49,50. This process is 
highly dependent on the capability of UCP1 to uncouple oxidative phosphorylation from ATP 
production (Figure 8)51,52. In unstimulated BAT, UCP1 is mainly inactive due to the inhibitory 
action of purine nucleotides. However, upon cold exposure or adrenergic stimuli, UCP1 
expression is increased, initiating the thermogenic process50,53,54. Even though adult 
humans were thought to not possess thermogenic fat cells, fluorodeoxyglucose positron 
emission tomography scans demonstrated metabolically active fat tissue in humans, as 
given by glucose incorporation rates55-57. In humans, BAT is mainly located within the 
supraclavicular, paravertebral and periadrenal areas, and is a highly vascularized and 
densely innervated tissue in order to enable the dissipation of heat throughout the body and 
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to sense adrenergic stimuli upon cold exposure, respectively. This constitutes an intricate 
complex that regulates mammal thermogenesis and enables body temperature 
maintenance44,50,58. 
 
Figure 8 | UCP1-dependent thermogenesis. The thermogenic ability of brown and beige adipocytes is conferred by 
uncoupling protein 1 (UCP1). UCP1 is located in the inner mitochondrial membrane and uncouples oxidative phosphorylation 
from ATP synthesis, releasing energy by dissipating the mitochondrial proton gradient at the expense of ATP production. This 
inducible proton leak can be repressed through the action of purine nucleotides and promoted through the action of long chain 
fatty acids. Adapted from Chouchani et al. Nat. Metab. 201959. 
 
Beige Adipocytes - Emerging Thermogenic Fat Cells 
Interestingly, emerging evidence has unveiled the role of a second class of 
thermogenic fat cells, termed beige or brite adipocytes. Clusters of thermogenic adipocytes 
can be found within some WAT depots, in response to prolonged cold exposure or β3-
adrenergic stimuli. Beige adipocytes share characteristics of both white and brown fat, 
depending on environmental cues60. When unstimulated, beige fat cells appear similar to 
white adipocytes. However, upon stimulation, beige cells acquire a multilocular appearance 
with densely packed UCP1-expressing mitochondria, which confers them thermogenic 
characteristics. This process is referred to as the ‘browning’ of WAT43. Recent reports have 
highlighted the role of thermogenic fat cells in humans. However, previously considered 
BAT in humans has now been revisited and described as beige fat depots, consistent with 
the view that brown adipocytes are lost during adulthood and beige cells develop as an 
evolutive conserved mechanism to provide plasticity in adaptive thermogenesis61. 
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 White, brown and beige adipocytes are distinct types of cells that greatly differ in 
their function. Whether WAT hypertrophic growth underlies the development of metabolic 
syndrome, BAT and/or beige fat cells activity may revert this process and improve 
metabolism. In an attempt to improve specific selection of different fat cells, several marker 
genes have already been described to distinguish white, brown and beige adipocytes. 
These markers include SLC7A10 for white fat; TBX1, TMEM26 and CD137 for beige 
adipocytes; and UCP-1, EVA1 and PRDM16 for brown fat cells45,60-63. 
 
Developmental Signature and Transcriptional Regulation 
Fat pads in adult humans seem to have a cohort of adipocyte progenitor cells in the 
vascular stromal fraction of adipose depots that ensure adipocyte renewal upon 
environmental stimuli. Adipogenesis refers to the process whereby fibroblast-like precursor 
cells commit to the adipogenic lineage, giving rise to mature adipocytes in a two-step 
process. Initially, a multipotent mesenchymal progenitor commits to the adipogenic lineage, 
followed by differentiation, where preadipocytes undergo growth arrest, accumulate lipids 
and form functional adipocytes (Figure 9)42,64,65.  
 
Figure 9 | Brown and white adipogenesis. White and brown adipocytes stem from different precursor cells. Brown 
adipocytes share a common MYF5+PAX7+ ancestor with myocytes. This precursor cell drives brown adipogenesis upon the 
influence of bone morphogenetic proteins (BMPs) and PR domain-containing 16 (PRDM16). White adipocytes can 
transdifferentiate into beige adipocytes through the action of diverse stimuli, including cold exposure which induce the 
expression of thermogenic-specific transcription factors, including PRDM16 and EBF2. From Cristancho et al. Nat. Rev. Mol. 
Cell Biol. 201141. 
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WAT depots initiate their development during late gestation, and adipogenic stimuli 
increases along with nutrient availability66. White adipocytes develop from PPARγ+ αSMA+ 
and PDGFRβ+ progenitor cells that reside near the vasculature66. Bone morphogenetic 
proteins have been described to promote adipocyte terminal differentiation triggering 
PPARγ transcription. In addition, different zinc finger transcription factors have been 
implicated in the commitment of adipocyte differentiation, sensitizing fibroblasts towards 
pro-adipogenic BMP signalling and promoting the expression of master regulators of 
adipogenesis PPARγ and co- activator CCAAT/enhancer binding protein-α (C/EBPα)65,67-69. 
Even though white and brown adipocytes were thought to stem from a common 
precursor cell, fate-mapping studies have unveiled different progenitor cells for both white 
and brown adipocytes70. BAT development precedes WAT adipogenesis during 
embryogenic development, taking into account the urgent need of newborns to maintain 
body temperature through non-shivering thermogenesis71. In vivo lineage tracing provided 
evidence for a common embryonic precursor cell for brown adipocytes and skeletal muscle 
that transiently express the transcription factors Pax7 and Myf5. The transcriptional 
regulator PRDM16 was found to determine the brown adipocyte phenotype72,73. The 
absence of PRDM16 in brown fat cells promotes myogenic differentiation. In fact, the 
methyltransferase EHMT1, an enzymatic component of the PRDM16 complex is critical to 
brown adipogenesis by repressing the activation of skeletal-muscle selective genes, 
enabling brown adipocyte differentiation74. 
Although beige adipocytes are characteristically similar to brown fat cells, these cells 
are developmentally distinct73. Similarly to white adipocytes, beige adipocytes are thought 
to derive from perivascular cells75. Even though the mechanisms of beige adipocyte 
maturation are still scarce, EBF2 and PRDM16 transcription factors are thought to play a 
role in beige adipogenic commitment, recruiting PPARγ to thermogenic gene targets, and 
initiating the adipogenesis of beige adipocytes73,76. Recently, ZFP423 has been 
documented to repress EBF2 transcriptional activity and to promote white adipocyte 
differentiation77. The brown-like adipocytes that develop within WAT depots in response to 
environmental cues may result from transdifferentiation of white adipocytes or from de novo 
adipogenesis from precursor cells. 
 
Adipose Tissue Microenvironment and Cellular Crosstalk 
Adipose tissue is a central metabolic organ compartmentalized in discrete depots 
and distributed throughout the human body. Adipocytes share their microenvironment and 
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interact with multiple cell types to coordinate adipose tissue functions. Vascular endothelial 
cells, sympathetic nerves, and immune cells compose the adipose tissue niche and 
modulate adipose function78. 
 
Angiogenesis 
Angiogenesis and vascular regression are critical processes for adipogenesis. WAT 
remodelling is dependent on energy consumption and host metabolic demands, which also 
depend on nutrients and hormones transport to and from adipose tissue for maintenance of 
systemic energy demands, underlying the importance of the angiogenic machinery58,79. In 
addition, white adipocyte progenitors are also described to reside within the mural cell 
compartment of the involving adipose vessels66. Ingrowth of blood vessels in AT increases 
blood perfusion and provides enough oxygen supply to adipogenic processes. Upon 
expansion, adipocytes and adipose-derived stem cells within the adipose compartment 
secrete high levels of proangiogenic factors, including FGF-2, VEGF, HGF, ANGPTL4, 
PDGFs and leptin that sustain angiogenesis and contribute to energy homeostasis58,80,81. 
Relative to WAT, BAT is a highly vascularized tissue and express higher levels of VEGF. 
This translates into an increased angiogenic profile within BAT, that contributes towards 
thermogenesis by providing the necessary oxygen and substrate (fatty acids and glucose) 
to sustain the organism thermic control44,58. Consistently, VEGF has been documented to 
increase beige and brown fat development and its expression has been demonstrated to 
be upregulated upon cold exposure82. 
 
Innervation 
Adipose tissue mass is intrinsically regulated by an endocrine loop that includes 
leptin release, which in turn acts upon neural circuits to regulate food intake and energy 
homeostasis83. Sympathetic innervation within adipose tissue regulates adipocyte function 
via the release of neurotransmitters, including brown adipogenesis and induction of 
adaptive thermogenesis44,53. Sympathetic nerve fibers density is directly correlated with 
beige fat adipogenesis, suggesting that beige fat development promotes nerve remodelling 
allowing for a more prominent thermogenic activation44. NGF and NRG4 are all adipocyte-
released nerve remodelling factors that are thought to promote nerve growth, differentiation 
and branching84. In particular, the neurotransmitter norepinephrine, also known as 
noradrenalin, is both able to impact brown and white adipocytes, whether it induces 
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thermogenic processes or mediates leptin-dependent lipolysis for fatty-acid release, 
underlying the importance of AT innervation towards improved metabolic homeostasis85. 
 
Immune Regulation 
Central to the metabolic homeostasis regulation is the immune compartment of the 
adipose tissue. Under normal conditions, adipose tissue is mainly composed of anti-
inflammatory immune cell populations. M2-like macrophages secrete a diverse array of 
cytokines including IL-4 and IL-10 that contribute towards insulin sensitivity and 
adipogenesis. Eosinophils maintain this alternatively activated macrophages in the AT 
microenvironment by secreting type II cytokines such as IL-4 and IL-1386. Type II cytokine 
signalling increases with cold exposure and contributes to lipolytic processes, beige adipose 
tissue remodelling and BAT activation. Importantly, M2-like macrophages are an important 
source of catecholamines and are thought to play a critical role in WAT browning, typically 
less innervated than BAT, creating a sympathetic nerve-independent pathway towards 
thermogenic processes87. ILC2s and regulatory T cells (Tregs) also contribute towards beige 
fat activation and are responsible for eosinophil activation and survival through the secretion 
of IL-5. Tregs are beneficial to homeostatic regulation, promoting alternative macrophage 
activation and improving insulin sensitivity via PPAR-γ expression88,89. Curiously, 
phenotypically distinct Tregs were described in both WAT and BAT depots, implying depot-
specific differences between different tissues90,91. Moreover, recent evidence suggests that 
WAT may function as a reservoir for memory T cells. Upon repeated infectious challenges, 
WAT suppresses lipid metabolic processes in favor of antimicrobial responses, allowing for 
long-term maintenance and rapid reactivation of memory T cells92.  
In the obese state, the hypertrophic adipocytes are more susceptible to inflammatory 
injury and cell death. The obese adipose tissue produces pro-inflammatory factors, 
including TNF, IL-6 and CCL2, recruiting monocytes that differentiate towards a pro-
inflammatory state. In fact, adipose tissue macrophages (ATMs) can comprise up to 40-
50% of all cells in obese individuals, contributing to the chronic inflammatory environment 
observed93. ATMs in obesity are polarized towards a pro-inflammatory state characterized 
by the expression of high levels of TNF and iNOS that contribute to metabolic disorder, 
impairing insulin sensitivity and inducing brown adipocyte apoptosis44,94,95. 
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Adipose Secretory Profile and Metabolism 
Prompted by the discovery of leptin and, a few years later, adiponectin, the 
physiology of adipose tissue highlights its role as an endocrine organ96. AT secretes a 
myriad of bioactive factors, termed adipokines, that contribute to the regulation of critical 
biological processes, including glucose maintenance, lipid, immune, and energy 
homeostasis84. These include white or brown adipocyte-derived secretory factors, including 
TNF, IL-6, FABP4, adiponectin, leptin, resistin, FGF21, NRG4, CCL2 and fatty acids95,97,98. 
Importantly, most of the above mentioned adipokines are upregulated in the obese 
state. The pro-inflammatory profile of obese individuals typically evolves to promote obesity-
linked metabolic diseases. The upregulation of these pro-inflammatory adipokines 
(particularly TNF, IL-6, leptin, resistin and CCL2) contribute to the development of a chronic 
inflammatory state and, ultimately, to metabolic dysfunction.  
Even though the alteration of the adipokine and lipid profile in response to nutritional 
cues are strongly associated with adipose tissue maladaptation, adiponectin is tightly 
associated with an anti-inflammatory profile of the healthy adipose tissue and increases free 
fatty acid oxidation and insulin sensitivity maintaining metabolic homeostasis. Contrarily, 
free fatty acid (including ceramides) ectopic deposition and spillover from adipocytes have 
lipotoxic effects, including mitochondrial dysfunction and insulin resistance. Notably, 
adiponectin, acting through its receptors AdipoR1 and AdipoR2, which possess ceramidase 
activity are thought to revert lipidic dysregulation and adipose tissue malfunction, 
decreasing ceramide levels within adipose depots. Arguably, leptin is the adipokine per se 
in the adipose compartment and is selectively expressed by adipocytes99. In healthy 
conditions, leptin has an essential role in suppressing appetite, energy expenditure and 
immune modulation. Therefore, it is not surprising that leptin-deficiency might lead not only 
to obesity, but also to an hyperglycemic condition and insulin-resistance100,101. Obesity 
usually increases the production of leptin. However, most of these individuals eventually 
develop leptin resistance, which is associated with elevated circulating levels of this 
adipokine and the inability of exogenously administrated leptin to decrease food intake and 
body weight, ultimately leading to a multitude of physiological alterations, including infertility, 
immune alterations and insulin resistance83,102. 
The contribution of the adipose tissue to homeostasis is remarkable. Minor 
alterations in the adipose tissue may lead to severe metabolic dysfunctions. Concordantly, 
it is invariably expected that adipose tissue also impacts cancer progression. 
 
                                                                                                                                                                            FCUP 
                 The Interplay Between Adipose Tissue and Renal Cell Carcinoma: Decoding the Obesity Paradox 
 
33 
 
ADIPOSE TISSUE AND CANCER INTERFACE 
 
Compelling evidence exist over the influence of the adipose tissue on cancer 
development. Excess adipose tissue accrual and AT dysfunction provides a unique 
microenvironment that favours both tumour initiation and progression. Even though 
increased adiposity is a well-established factor for cancer incidence and mortality, 
mechanistic insights that disclose the influence of this obese setting on cancer progression 
are currently scarce. Therefore, a better understanding of the processes through which 
adipose tissue expansion promotes tumourigenesis is critical to decrease obesity-related 
cancer incidence and improve treatment. 
 
Epidemiologic Evidence for Obesity-Related Cancer 
Obesity ensues a state of excessive accumulation of adipose tissue when caloric 
food intake largely exceeds energy expenditure. Excess adipose tissue is tightly associated 
with metabolic dysfunction and predisposition to several metabolic disorders, including type 
2 diabetes mellitus and cardiovascular diseases. Ample large-scale epidemiological studies 
have unraveled a strong association between obesity and the risk of cancer 
development103,104. Obesity is estimated to contribute to approximately 9% of all cancers 
and 5-20% of all cancer-related deaths, promoting not only carcinogenesis, but the tumour 
development of established cancers as well103,105. In fact, evidence linking obesity to cancer 
development in the oesophagus, colon, kidney, pancreas, liver, thyroid, breast and 
endometrium is well established106,107. Intentional weight loss and/or bariatric surgery 
decrease cancer incidence, further supporting a role of excess adipose tissue in cancer108. 
At the same time, localized abdominal obesity has been specifically linked with cancer 
progression109. The interrelationship between the cellular and molecular pathways that are 
involved in obesity-associated tumourigenesis remain elusive. However, a number of 
mechanisms that link obesity with established and emerging hallmarks of cancer have been 
proposed, including inflammation, angiogenesis, immune regulation, EMT, genomic 
instability and cellular energetics12,110. 
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Adipose Tissue Microenvironment and Cancer Progression 
The survival of cancer cells is intricately related to its dependency on interacting with 
surrounding non-malignant tumour stroma cells. Adipose tissue within the tumour stroma 
actively contributes to tumour growth and metastasis providing an energetic reservoir for 
embedded cells. Signalling molecules secretion, including adipokines, proinflammatory and 
proangiogenic factors and ECM constituents exacerbate the importance of the AT as a 
critical contributor to cancer development and recurrence (Figure 10)111,112.  
 
Figure 10 | Adipose tissue promotes malignant transformation and tumour development. Adipose tissue hypoxic 
hypertrophic expansion promotes the establishment of a chronic inflammatory state that may contribute to tumour initiation 
and progression. The adipose depot secretes a myriad of ECM constituents and growth factors that contribute to angiogenesis 
and mitogenic signalling that ultimately leads to tumour growth and invasive-associated features, including chemoresistance 
and dissemination. From Lengyel et al. Trends Cancer 2018113. 
Importantly, several features are shared between hypertrophic expansion of adipose 
tissue in the obese state and solid tumour growth. Tumour hypoxia is recurrently associated 
with worse outcomes for cancer patients and resistance to chemotherapy114. Concordantly, 
unbalanced adipose tissue expansion also induces hypoxia, triggering a series of 
compensatory angiogenic mechanisms to surpass nutrient and oxygen limited supply58. 
Similar to carcinogenic processes, profibrotic pathways are upregulated within the obese 
adipose microenvironment upon hypoxic conditions through the induction of HIF-1α-related 
pathways. Hypoxic adipose tissue upregulates the levels of ECM proteins (including 
collagens, matrix metalloproteinases and tissue inhibitors of metalloproteinases) and 
proinflammatory cytokines (such as TNF, IL-6 and CCL2), providing a tumour-permissive 
niche for transformed infiltrating cells (Figure 11)115,116. Notably, several proinflammatory 
and fibrotic molecules distinctive of obese individuals have been directly implicated in 
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tumour growth and metastasis. For instance, endotrophin, a C-terminal cleavage product of 
COL6α3 chain, has been reported to directly trigger adipose tissue fibrosis and metabolic 
dysfunction as well as promoting malignant tumour progression in mammary tumours117,118. 
 
Figure 11 | Obese tumour microenvironment. During dysregulated hypertrophic growth of adipose tissue, the tumour niche 
is remodelled. Importantly, obesity promotes interstitial fibrosis altering ECM mechanotransduction. The tumour 
microenvironment within an obese state is enriched in adipose-derived stem cells that can into fibroblasts or adipocytes 
depending on environmental cues and tumour requirements to support tumour growth. In the obese-related cancer 
microenvironment the number of adipocytes is enriched, supporting tumour growth by providing tumour cells the fuel 
necessary to rapid cancer expansion. From O’Sullivan et al. Nat. Rev. Gastroenterol. Hepatol. 2018104. 
 
Inflammation as a Protumourigenic Mechanism 
Unbalanced excess caloric intake and adipocyte hypertrophic growth leads to 
alterations in insulin sensitivity and cellular stress within fat cells given the surplus lipid 
accumulation and the oxidative stress, resultant from deficient neoangiogenic processes 
occurring within the obese state. The consequent hypoxic environment and lipid spillover 
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result in the release of inflammatory adipokines and in the increase on immune infiltrating 
cell rates, eventually leading to both local and distant chronic infllamation119. Chronic 
inflammation denotes a prolonged and dysfunctional protective mechanism that emerges in 
response to loss of tissue homeostasis, and has already been implicated as one of the 
hallmarks of cancer and underlying mechanistic process for tumourigenesis12,120,121. In lean 
individuals, adipose tissue immune infiltrate maintains tissue homeostasis, contributing to 
the clearance of apoptotic cells, angiogenic regulation and ECM remodelling, preserving a 
balanced microenvironment. In contrast, in obese subjects, immune cells often shift their 
phenotypic properties, promoting inflammation and consequent fibrosis122. The resulting 
fibrotic remodelling increases tissue stiffness and mechanotransduction, promoting 
carcinogenesis123. 
Even though AT-secreted molecules do not necessarily have mutagenic potential, it 
is plausible that the dysfunctional adipose tissue enhances mitogenic signalling to cells that 
already have carcinogenic mutations. However, genotoxicity is known to result from 
oxidative stress. The hypoxic AT microenvironment induces the production of reactive 
oxygen species (ROS) that, in turn, might cause DNA damage and impaired DNA 
repair124,125. In dysfunctional adipose tissue from obese patients, inflammatory signals 
recruit myeloid cells that apparently represent the major source of ROS within the AT, 
creating a chronic inflammatory state that ultimately conducts to genomic instability accrual 
and tumour initiating processes126. 
These processes are mainly elicited from adipocytes that prompt the adipose 
microenvironment through the secretion of a myriad of adipokines that modulate its 
environment and impact tumour development. However, not only adipocytes are 
responsible for the effects of this tissue on cancer initiation and progression127. The vascular 
stromal fraction of the AT, and in particular, the immune and adipose-derived stromal cells 
are critical players on adipose tissue landscape. 
 
Adipose Immune Landscape and Cancer Cell Interactions 
Adipose tissue contains a multitude of immune cells that contribute to cancer, from 
which macrophages are the most represented population122. These numbers increase in 
the setting of obesity, once adipocytes recruit and activate macrophages via CCL2 
production, the major chemoattractant of monocytes to the obese tumour 
microenvironment128. AT-resident leukocytes may drive the tumourigenic process by 
systemically releasing an array of cytokines. It is also plausible that these cells are recruited 
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to the tumour microenvironment and act locally and/or at the AT-tumour invasive front. In 
fact, in obese individuals, AT-associated macrophages and tumour-associated 
macrophages are phenotypically and functionally similar, suggesting that AT macrophages 
may provide an identical activated microenvironment to that found in tumours129,130. Both 
populations induce fibrosis, angiogenesis and local hypoxia. The shift in the macrophage 
landscape from anti-inflammatory to proinflammatory leads to the above mentioned chronic 
inflammatory state and to alterations in lipid metabolism, which further contributes to cancer 
progression. In addition, a pool of cytokines released by these macrophages contributes to 
malignancy, promoting growth, ECM remodelling and tumour angiogenesis. The presence 
of aggregates of macrophages and of other immune cells around dead adipocytes, termed 
‘crownlike structures’, is associated with increased aromatase levels and inflammation that 
potentiate cancer progression. Importantly, increased numbers of macrophages within 
breast cancer tumours are associated with high tumour grades and poor prognosis131-133. 
Even though only a few studies have dissertated over the influence of lymphocytes 
in the obese AT in cancer, these are undoubtedly important players in the TME. Notably, 
there is enrichment of activated and effector CD4+ and CD8+ T cells in the obese AT. These 
cells further exacerbate inflammatory macrophage recruitment and inflammatory cytokine 
production, including the secretion of MMPs, VEGF, TNF, IL-6 and CCL2, sustaining 
obesity-associated inflammation122,134,135. Importantly, obesity is thought to have a role in 
PD-1 regulation and immune tolerance. AT-associated macrophages expression of PD-L1 
is upregulated by HIF-1α during hypoxia. At the same time, obesity promotes PD-1 
expression in T cells, suppressing immunosurveillance and increasing immune 
tolerance136,137. 
Invariant natural killer cell (iNKT) numbers are usually increased in visceral adipose 
tissue of healthy humans. However, these cells are nearly absent from adipose tissue 
depots upon obesity. These cells are capable of recognizing lipid antigens, regulate 
adaptive immunity and are important players in the clearance of tumour cells138. However, 
iNKTs functional features and viability are impaired upon obesity and may further drive 
oncogenic processes139. 
 
Adipose-Derived Stem Cells 
Adipocyte progenitors, termed adipose-derived stem cells (ASCs), are part of the 
stromal vascular fraction of the adipose tissue. This population is enriched within the obese 
setting and might be mobilized and recruited from adipose compartments to tumours to 
sustain cancer cell demands. CXCL1 and CXCL8 mediate the homing of ASCs to tumour 
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sites, where they may be incorporated into blood vessels as pericytes, or differentiate into 
multiple cell lineages, including adipocytes and cancer-associated fibroblasts140-142. 
Infiltrating ASCs within the tumour microenvironment directly impact cancer progression, 
driving tumour desmoplasia, recruiting macrophages and secreting proangiogenic factors, 
evidencing its tumour-promoting role123,143. ASCs have already been implicated in the 
growth, invasive potential and chemoresistance in ovarian and breast cancer144,145. 
Additionally, ASCs also contribute towards epithelial to mesenchymal transition during 
obesity-associated cancer by abnormally expressing leptin levels. Even though the exact 
mechanisms through which these cells are capable to impact tumour growth are still 
unresolved, the importance of ASCs crosstalk with cancer cells is undeniable, promoting 
cancer invasion and metastasis146. 
 
Tumour-Adipocyte Specific Interactions 
Several types of carcinoma are known to invade adjacent adipose tissue. Therefore, 
it is not surprising that adipocytes directly interact with malignant cells in a bidirectional 
manner and contribute to tumour maintenance and progression111,113. In a subset of 
tumours, including breast, prostate, ovarian, colon, acute myeloid leukemia and renal 
cancers the adipocyte-rich microenvironment promote cancer growth and reflect a role for 
adipocytes in tumour development111,112. Notably, the crosstalk between adipocytes and 
cancer cells lead to considerable morphological and functional modifications: i. increases in 
adipocyte delipidation, ii. promotion of secretory proinflammatory molecules (including IL-6, 
IL-8 and PAI-1) and, iii. decrease in adipocyte terminal differentiation markers. Therefore, 
cancer associated adipocytes (CAAs) become tumour-educated and acquire a fibroblast-
like and cancer-promoting phenotypes (Figure 12) 147-149. 
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Figure 12 | Cancer cells and cancer-associated adipocytes crosstalk. The interaction between cancer-associated 
adipocytes (CAAs) and cancer cells promotes the creation of a niche that is permissive for tumour growth and metastasis. 
Cancer cells stimulate adipocytes delipidation and the acquisition of a fibroblast-like phenotype. CAAs decrease adipocyte 
terminal differentiation markers and increase the secretion of inflammatory cytokines and proteases that increase tumour 
progression and invasive potential. The rapid growth of tumour cells is accompanied by the release of free fatty acids by CAAs 
that support tumour growth and provide the necessary energy to fuel tumour development. From Park et al. Nat. Rev. 
Endocrinol. 2014112. 
 
Cellular Energetics and Metabolic Symbiosis - Beyond the Warburg Effect 
Tumour cells often shift their metabolic status, generating ATP via glycolytic 
processes rather than oxidative phosphorylation even under aerobic conditions12. Emerging 
insights over the metabolic features of cancer cells have suggested that aerobic glycolysis 
occurs in tumour surrounding cells rather than in cancer cells itself, providing to malignant 
cells the necessary nutrients, via a paracrine exchange, to generate energy by 
mitochondrial oxidative metabolic processes150,151. CAAs survival-promoting effect on 
tumours are increasingly being associated with metabolic symbiosis, suggesting that 
adipocytes within the TME provide nutrients to cancer cells, sustaining tumour growth and 
survival152-155. 
With hypoxia, occurring metabolic reprogramming in cancer cells increase lipid 
usage, associated with cancer aggressiveness. The primary source of lipids used by cancer 
cells are fatty acids (FAs). In fact, FAs utilization is a more efficient way to produce energy 
through β-oxidation since it allows cells to increase energetic yields relatively to 
glucose156,157. Importantly, FAs derivatives are important are important components of 
cancer cell structure and mitochondrial membrane, further supporting tumourigenesis158. 
Transformed malignant cells are capable of synthesizing FAs de novo and abnormally 
elevated lipogenesis is a hallmark of aggressive and metastatic cancers159,160. However, in 
rapid growing and more aggressive cancers, endogenous lipogenesis becomes limiting and 
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tumour cells increase the uptake of extracellular FAs161. Cancer associated adipocytes 
hydrolyze triglycerides to release free FAs and consequent uptake by malignant cells. In 
this regard, FABP4, a FA-binding protein, mediates the trafficking of adipocyte-derived FAs 
between CAAs and cancer cells. In turn, transformed cells upregulate the levels of CD36, 
which facilitates FA uptake, enabling the usage of FAs as a substrate for β-oxidation, 
providing the tumour with sufficient energy requirements for growth and progression153-155. 
Notably, in the obese setting, increased levels of systemic adipocyte-derived FABP4 
promotes mammary tumour stemness and aggressiveness162. Moreover, overexpressing 
CD36 cells were demonstrated to boost the metastatic potential of oral squamous cell 
carcinomas163. Therefore, adipocyte-derived FAs might constitute an important substrate to 
support tumour growth and metastasis and may provide novel therapeutic approaches to 
treat different cancers. 
 
Focus on Leptin and Adiponectin 
Leptin is an adipocyte-derived hormone that regulates appetite and energy 
homeostasis46. Leptin levels are intrinsically correlated with increased adiposity in humans, 
and studies have associated this hormone with increased cancer incidence in obesity. 
Leptin signals through a transmembrane receptor (OBR) that mediates intracellular 
signalling through STAT3, increasing pro-inflammatory signalling within the cell, which 
promotes cancer progression164. Moreover, leptin functions to promote mitogenic effects, to 
mediate immune suppression and to support angiogenesis165. Furthermore, leptin is thought 
to induce telomerase reverse transcriptase expression, EMT and stemness166-168. In 
summary, leptin may promote tumour progression. 
Adiponectin is an adipokine with pleiotropic actions, including insulin-sensitizing, 
anti-inflammatory and anti-apoptotic functions, and regulates multiple processes, including 
glucose and lipid metabolism169. In the obese setting, adiponectin levels are negatively 
correlated with adipose mass, and this decrease is associated with cancer 
aggressiveness164,170. Both indirect and direct effects of adiponectin in cancer progression 
have been elucidated. Adiponectin binding to its receptors (ADIPOR1 and ADIPOR2) 
sequesters growth factors, activating AMPK signalling while impairing several other 
intracellular mediators (including ERK1 and ERK2, PI3K-AKT, WNT-β-catenin and STAT3 
signalling), which negatively impacts fatty acid and protein synthesis, cellular growth and 
proliferation, while enhancing genomic toxicity, increasing cell cycle arrest and apoptosis. 
Therefore, adiponectin appears to have a protective role in carcinogenesis171,172. 
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ADIPOSE TISSUE AT THE NEXUS OF RENAL CELL CARCINOMA 
 
Obesity pandemics is a mounting health concern worldwide and is associated with 
increased risk to develop multiple types of cancer, including renal cell carcinoma. RCC 
comprises over 90% of all kidney cancers and is tightly associated with excess adiposity. 
In fact, a 5 kg/m2 increase in body mass index (BMI) is strongly correlated with the risk to 
develop RCC106. Tumours invade stromal compartments that are enriched in adipose tissue, 
and the ensuing crosstalk shapes the tumour microenvironment and contributes to cancer 
progression173. Importantly, several reports indicate towards a counterintuitive premise, 
known as the ‘obesity paradox’: even though excess adiposity is associated with RCC 
development, obese patients, defined as a BMI ≥ 30, had a median overall survival superior 
to lean individuals174-178. Moreover, even though the mechanisms that contribute to this 
‘obesity paradox’ are largely unknown, different studies have pointed towards a role of 
decreased adiponectin175 allied to an increase in FASN174 levels in obesity-related cancer-
specific survival. 
Currently, mechanisms linking obesity with RCC incidence are mainly unknown. 
Studies performed on diet-induced obesity animal models illustrated a relationship between 
the obese adipose compartment and renal cancer, where obesity promotes an 
immunosuppressive environment, increasing myeloid-derived suppressor cells 
accumulation and impairing dendritic cell response to RCC179,180. Moreover, cell line-based 
studies unveiled an effect of perirenal adipose tissue (PrAT) on migration and invasive 
potential of RCC, and propose a potential role of WNT signalling on disease 
progression181,182. 
Although only a few studies have disserted over the influence of the AT in RCC, a 
clearer picture of the crosstalk between both tissues is underway. However, further studies 
are in need to fully disclose the role of the adipose organ in cancer and, particularly, in renal 
cell carcinoma. 
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AIMS 
 
The interrelationship between clear cell renal cell carcinoma (ccRCC) and 
surrounding adipose tissue (AT) is still very scarce. This project sets to provide insight over 
the ensuing crosstalk between clear cell renal cell carcinoma and the adipose tissue, 
focusing on the nexus between the perirenal and subcutaneous adipose depots and 
ccRCC. Several studies portray the impact that different adipose tissues have on distinct 
types of cancer. The ccRCC/AT interface is of particular importance since, even though 
obesity increases the relative incidence of this type of cancer, obese patients have superior 
overall survival rates than its counterpart lean individuals. To address this issue, this project 
sets its basis on three main specific aims: 
1. To give a comprehensive characterization of both perirenal and subcutaneous 
adipose depots, establishing the distinct features of both ATs and assess its 
influence on clear cell renal cell carcinoma.  
2. To evaluate the influence of adipose tissue-derived secreted factors on clear cell 
renal cell carcinoma genetic signature. 
3. To address the role of adipose tissue in the functional activity of clear cell renal 
cell carcinoma cells, specifically, proliferative and apoptotic processes. 
The conclusions drawn from this work will increase the amount of growing evidence 
that interconnects the adipose depot with clear cell renal cell carcinoma and sets some 
groundbreaking insights to potentiate novel research and therapeutic strategies that target 
adipose function in the treatment of ccRCC. 
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MATERIALS AND METHODS 
 
 
Clinical Samples and Adipose Tissue Ex Vivo Culture 
Human perirenal (PrAT) and subcutaneous (ScAT) adipose tissue samples were 
collected from renal cell carcinoma patients undergoing radical or partial nephrectomy in 
accordance with the recommendations of the ethics committee of the participating Hospitals 
(Centro Hospitalar do Porto e Centro Hospitalar do Alto Ave). All patients gave their 
informed consent to participate in this study, which was conducted according to the 
Declaration of Helsinki Principles. PrAT and ScAT samples were collected, transported in 
Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12 (DMEM/F12) (Gibco, Invitrogen) 
supplemented with 10% of newborn calf serum (NBCS) and immediately processed. Tissue 
was dissected to remove major vessels and further parted into 5-10 mm pieces and washed 
several times with PBS upon processing. Explants were cultured for 16h in DMEM/F12 
supplemented with 10% of NBCS (0.3 g of explant/ml medium) and incubated at 37ºC, 5% 
CO2. Following the 16h of culture, the medium was renewed and fresh non-supplemented 
DMEM/F12 was added. Explants were maintained at 37ºC, 5%CO2. After 48 hours, the 
undernatant was collected, centrifuged (5 min, 1500 g), aliquoted and stored at -80º as 
explant conditioned medium (CM). 
 
Cell Lines Maintenance and Culture Conditions 
786-O and Caki-1 RCC cell lines (Table 1) were cultured in RPMI-1640 (Gibco, 
Invitrogen) and McCoy’s 5A (Gibco, Invitrogen) media, respectively. Media were 
supplemented with 1% penicillin-streptomycin (Pen/Strep) (Biowest, 100x, cat no. L0022-
100) and 10 % fetal bovine serum (FBS) (Biowest, cat. Nº S181BH-500). Cell lines were 
maintained at 37ºC in a humidified atmosphere of 5% CO2. The cells were detached with 
0.05% trypsin (Sigma-Aldrich, T4799) for 5- 10 minutes at 37ºC and its action was 
neutralized using RPMI-1640 or McCoy’s 5A medium containing 1% Pen/Strep (Biowest) 
and 10% FBS (Biowest). The cells were used for assays when >80% confluence was 
reached. 
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            Table 1 | Clear cell renal cell carcinoma lines. 
 
 
 
 
 
 
 
Adipocyte Size Measurements 
Adipocyte area size was determined from H&E stained paraffin sections of both 
perirenal and subcutaneous adipose tissue. Cross-sectional area of adipocytes was 
obtained from perimeter tracing of cells using ImageJ. At least 100 adipocytes were 
quantified for each patient. 
 
Cell Proliferation 
786-O (1.5 x 104 cells/well) or Caki-1 (2.0 x 104 cells/well) cell lines were seeded 
into 6-well plates in complete RPMI-1640 or McCoy’s 5A complete media, respectively, and 
cultured for 24 hours at 37ºC, 5% CO2. Following incubation period, media was removed, 
and cells were washed with PBS three times and the medium renewed with RPMI-1640 or 
McCoy’s 5A complete media with (50% volume) or without (control) adipose tissue-derived 
conditioned medium. Cell lines were maintained at 37ºC in a humidified atmosphere of 5% 
CO2. 24 hours later, cells were detached and stained with EdU using Click-iT™ Plus EdU 
Alexa Fluor™ 647 Flow Cytometry Assay Kit (Invitrogen, cat no. C10634) according to 
manufacturer’s instructions. Following staining, samples were filtered, and cells were 
acquired on a FACSCanto flow cytometer (BD Biosciences) using FACSDiva software. Data 
analysis was performed with FlowJo software. 
 
Cell Line VHL Status Derived From 
786-O Inactivating mutation Primary Tumour 
Caki-1 Wild Type Skin Metastasis 
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Apoptosis Assay  
786-O (1.5 x 104 cells/well) or Caki-1 (2.0 x 104 cells/well) cell lines were seeded 
into 6-well plates in complete RPMI-1640 or McCoy’s 5A complete media, respectively, and 
cultured for 24 hours at 37ºC, 5% CO2. Following incubation period, media was removed, 
and cells were washed with PBS three times and the medium renewed with RPMI-1640 or 
McCoy’s 5A complete media with (50% volume) or without (control) adipose tissue-derived 
conditioned medium. Cell lines were maintained at 37ºC in a humidified atmosphere of 5% 
CO2. 24 hours later, cells were detached and stained with FITC Annexin V and propidium 
iodide (PI) using FITC Annexin V Apoptosis Detection Kit I (BD Biosciences, cat no. 556547) 
according to manufacturer’s instructions. Following staining, samples were filtered, and 
cells were acquired on a FACSCanto flow cytometer (BD Biosciences) using FACSDiva 
software. Data analysis was performed with FlowJo software. 
 
Zymography 
Conditioned media from perirenal and subcutaneous adipose tissues were analysed 
by gelatin zymography. Protein content was determined using the DC protein assay kit 
(BioRad), and 15 µg of protein were mixed with a non-reducing sample buffer (10% SDS, 
4% sucrose, and 0,03% bromophenol blue in 0.5 M Tris-HCl pH 6.8) and PBS. Separating 
(10% polyacrylamide, 0.1% gelatin (Bovine skin type B, Sigma G9391) and stacking (2,5% 
polyacrylamide) gels were prepared. The samples were loaded and separated for 
approximately 4 hours at 80V. After electrophoresis, gels were washed twice with 2% Triton 
X-100 for protein renaturation. The gels were incubated for 16 hours at 37 ºC in MMP 
substrate buffer (50 mM Tris-HCl; pH 7.5, 10 mM CaCl2 and 0,5 % NaN3). After the 
incubation, gels were stained with Coomassie Blue solution (Sigma Aldrich) for 
approximately 30 minutes followed by a wash with deionized water. White bands of 
proteolytic degradation appeared on a blue background. Finally, the gels were scanned and 
the MMPs molecular weight and activity was estimated by densitometric analysis 
(QuantityOne, BioRad). 
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RNA Extraction and Purification 
 
 Adipose Tissue 
Perirenal and subcutaneous adipose tissue were preserved in RNAlater RNA 
Stabilization Solution (Invitrogen, cat no. AM7020). Total RNA was extracted from 100 mg 
of tissue was lysed in 1.2 mL of QIAZOL Lysis Reagent and homogenized with 
TissueRuptor II (QIAGEN, cat no. 9002756), using disposable probes. RNA was purified 
using the RNeasy Lipid Tissue Mini Kit (QIAGEN, cat no. 74804) according to 
manufacturer’s instructions.  
 Cell Lines 
Total RNA was extracted from the cells previously cultured in perirenal- or 
subcutaneous AT-derived CM. After detachment, cells were centrifuged at 1200 rpm for 5 
minutes at 4ºC, resuspended in 500 μL of TriPure Isolation Reagent (Roche, ref. 
11667165001) in a fume hood and according to the manufacturer´s instructions, and 
transferred into 1,5 mL eppendorf tubes. The cells were then stored at -80º C until further 
use. For the RNA extraction, the cells were incubated for 5 minutes at RT to ensure the 
complete dissociation of nucleoprotein complexes. After incubation, 100 μL of chloroform 
were added to each sample and the tubes were shaken vigorously for approximately 15 
seconds. The tubes were then incubated at RT for 15 minutes and centrifuged at 12000g 
for 15 minutes at 4ºC in order to separate the solution into three phases. After the 
centrifugation, the colorless upper part of the solution was transferred into new tubes. In 
order to precipitate the RNA, isopropanol was added (250 μL per tube) and the tubes were 
gently inverted manually, followed by an incubation at RT for 10 minutes. Afterwards, the 
tubes were centrifuged at 12000g for 10 minutes at 4ºC and the supernatant was discarded. 
Ethanol was added (500 μL per tube) and the RNA was washed by vortexing, and then 
centrifuged at 7500g for 5 minutes at 4ºC. The supernatant was discarded and the excess 
ethanol from the RNA pellet was removed by air drying for at least one hour. Subsequently, 
each pellet was resuspended in 20 μL of RNAse-free water and incubated for one hour at 
4ºC. RNA concentration and purity were analysed using a Nanodrop Spectrophotometer 
ND1000 (Thermo Scientific). The RNA samples were stored at -80ºC until further use. 
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Complementary DNA First-Strand Synthesis 
The synthesis of cDNA was performed using 400 ng (for adipose tissue) or 1 µg (for 
cell lines) of RNA. Two independent mixes were prepared. The first mix (annealing mix) 
was prepared with 1 µg of the previously extracted RNA, 1 µL of random primers and 9 µL 
of RNAse/DNase free water. The mix was then incubated for 10 minutes at 70 ºC using a 
thermocycler (BIOMETRA T1 Thermoblock Thermal Cycler). The second mix was 
composed of 4 µL of 5x first-strand buffer (Invitrogen), 1 µL of 10 mM dNTPs Mix 
(Invitrogen) 2 µL of 0,1 mM DTT (Invitrogen), 0,2 µL of NZY Ribonuclease Inhibitor 
(nzytech), 0,5 µL 52 of Reverse Transcriptase (nzytech) and 1 µL of RNAse/DNase free 
water (Invitrogen). After the incubation of the first mix, 8 µL of the second mix was added to 
the annealing mix and incubated for 1 hour at 37ºC using the previously mentioned 
thermocycler. The obtained cDNA was stored at -20º until further use. 
 
Quantitative Real-Time PCR 
After the cDNA synthesis, qRT-PCR was carried out using a TaqMan Universal PCR 
Master Mix (KAPA PROBE FAST qPCR Master Mix, lKAPA Biosystems) and probes for 
UCP1, PRDM16, EVA1, TBX1, TMEM26, CD137, SLC7A10, HIF1α, HIF2α, IL6, TGFβ1, 
SNAIL, SLUG, ZEB1, ZEB2, TWIST1, OCT4, NANOG and TBP or GAPDH (used as 
housekeeping genes for AT and cell lines, respectively) (Table 2). The qRTPCR was 
performed in a 7500 Real Time PCR system (Applied Biosystems). The program was 1 step 
of 95 ºC for 20 seconds followed by 40 cycles of 95ºC for 3 seconds and 60 ºC for 30 
seconds. Each reaction was executed in triplicate and relative mRNA expression of the 
target genes was normalized to the levels of the housekeeping gene using the comparative 
ΔΔCT method. 
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Table 2 | Gene assays for qRT-PCR. All probes used were supplied by Integrated DNA Technologies (IDT) 
 
Statistical Analysis 
All the data obtained in this work was organized and analysed using the GraphPad 
Prism 6 software. Data were analyzed for Gaussian distribution using D’Agostino-Pearson 
or Shapiro-Wilk normality tests. Statistical tests are registered in the figures’ captions. The 
significance was defined as P ≤ 0.05. 
 
 
 
Gene Assay ID Gene Assay ID 
UCP1 Hs.PT.58.39157006 TGFβ1 Hs.PT.58.39813975 
PRDM16 Hs.PT.58.25688289 SNAIL Hs.PT.58.2984401 
EVA1 Hs.PT.58.996348 SLUG Hs.PT.58.1772559 
TBX1 Hs.PT.58.2672803 ZEB1 Hs.PT.58.39178574 
TMEM26 Hs.PT.58.4285425 ZEB2 Hs.PT.58.1089006 
CD137 Hs.PT.58.40744808 TWIST1 Hs.PT.58.18940950 
SLC7A10 Hs.PT.58.25903360 OCT4 Hs.PT.58.14648152.g 
HIF1α Hs.PT.58.534274 NANOG Hs.PT.58.21480849 
HIF2α Hs.PT.58.2273374 TBP Hs.PT.58.20792004 
IL6 Hs.PT.58.40226675 GAPDH Hs.PT.39a.22214836 
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RESULTS 
 
 
ADIPOSE TISSUE CHARACTERIZATION 
Renal cell carcinoma malignant cells may influence the surrounding adipose tissue 
to acquire phenotypic features that benefit tumour growth. Furthermore, cancer cells 
influence distant niches in order to promote metastatic behaviour. In this work, two distinct 
adipose depots were used to understand the role of depot-specific influences on ccRCC. 
Notably, and even if the peritumoural adipose tissue is of crucial importance in the tumour 
landscape, the usage of a different distant depot, as the subcutaneous AT, to understand 
the relative influence of individual fat pads in ccRCC is mandatory. It is of utter importance 
to, firstly, characterize the different depots to assess the existence of intrinsic differences 
between perirenal (PrAT) and subcutaneous (ScAT) adipose tissues. A characterization of 
the above-mentioned depots will be conceded in this section, which will comprehend 
morphological, genetic and functional analysis of the distinct adipose repertoires that will 
constitute the foundation for the rest of this work. 
 
Perirenal and Subcutaneous Adipose Tissue Have Distinct 
Morphological Features 
 To assess the differences between perirenal (PrAT) and subcutaneous (ScAT) 
adipose depots, the morphological appearance of PrAT was compared to that of ScAT 
(Figure 13). Hematoxylin and eosin (H&E)-stained paraffin-embedded sections of both 
adipose depots were analysed regarding its morphological aspect (Figure 13A). No 
apparent differences could be observed between PrAT and ScAT. Both depots presented 
an unique large unilocular lipid droplet occupying most of the cell cytoplasm. However, 
visual differences could be detected when comparing the adipocyte size between both 
tissues (Figure 13A). In fact, microscopic determination of the cross-sectional area of 
individual adipocytes from the two different tissues revealed a significant difference between 
PrAT and ScAT. These measurements demonstrated an increased size regarding PrAT 
adipocytes in comparison to ScAT fat cells (Figure 13B). 
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Figure 13 | Perirenal and subcutaneous adipocytes have distinct sizes. H&E stained paraffin embedded sections from 
perirenal (PrAT) and subcutaneous (ScAT) adipose tissues collected from renal cell carcinoma (RCC) patients submitted to 
partial or radical nephrectomy were analysed. (A) Representative images of H&E cross-sectional sections (200x ampliation) 
of both perirenal (left) and subcutaneous (right) adipose depots. (B) Microscopic quantification of individual adipocytes area 
in PrAT (n=7) and ScAT (n=6) of the aforementioned H&E-stained sections. Bars represent mean values and error bars 
represent standard deviation (SD). **p < 0.01 as determined by unpaired two-tailed Student’s t test. 
In summary, morphological analysis disclosed the first evidence for distinct site-
specific features between PrAT and ScAT in this work. 
 
 
 
 
 
 
                                                                                                                                                                            FCUP 
                 The Interplay Between Adipose Tissue and Renal Cell Carcinoma: Decoding the Obesity Paradox 
 
51 
 
Perirenal Adipose Tissue Displays a Trend to Increase 
Thermogenic-Selective Genes 
Following adipose morphological characterization, a genetic-based approach of a 
panel of genes known to be differentially express in white, brown and beige adipocytes was 
conducted. RNA extracted from perirenal and subcutaneous adipose tissues collected from 
RCC patients that were submitted to partial or radical nephrectomy was used to assess 
relative mRNA expression levels of UCP1, PRDM16 and EVA1 (brown-selective genes); 
CD137, TMEM26 and TBX1 (beige-selective genes); and SLC7A10 (white-selective gene) 
(Figure 14). 
Overall, the levels of brown-selective genes underlined a trend for PrAT to 
upregulate the expression of these genes when compared to ScAT (Figure 14, upper 
panel). Importantly, even though not statistically different, UCP1 gene expression levels 
were higher in all PrAT samples than in ScAT counterparts (data not shown). However, no 
differences could be seen regarding to PRDM16. 
Whereas CD137 levels tended to increase in ScAT, TMEM26 observed expression 
was the opposite. TMEM26 presented increased levels in PrAT when compared to ScAT. 
No major differences could be observed when comparing the mRNA expression levels of 
TBX1 between both depots (Figure 14, lower panel, left). 
Even though the levels of brown-like genes were relatively increased in PrAT, this 
tissue significantly increased SLC7A10 expression levels compared to ScAT (Figure 14, 
lower panel, right).  
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Figure 14 | Gene expression profile of perirenal (PrAT) and subcutaneous (ScAT) adipose depots. RNA extracted from 
paired PrAT and ScAT collected from RCC patients submitted to partial or radical nephrectomy was reverse transcribed and 
analysed by quantitative real-time PCR (qRT-PCR). A panel of marker genes for brown (UCP1, PRDM16 and EVA1), beige 
(CD137, TMEM26 and TBX1) and white (SLC7A10) adipocytes were assessed and its mRNA levels determined (n=5). 
Relative gene expression was normalized to TATA box-binding protein (TBP) mRNA levels. Bars represent mean values and 
error bars represent standard deviation (SD). *p < 0.05 as determined by paired two-tailed Student’s t test. 
Altogether, PrAT collected from RCC patients evidenced a thermogenic gene 
program signature, given the trend to enhance the expression of both brown- and beige-
selective genes, when compared to ScAT, even though higher levels of the white-selective 
gene, SLC7A10, could also be found in this depot.  
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Perirenal Adipose Depot Secretes Higher Amounts of Matrix 
Metalloproteinases  
Matrix metalloproteinases (MMPs) are proteolytic enzymes that have long been 
associated with cancer cell invasive and metastatic potential through ECM remodelling,  and 
the regulation of tumour angiogenesis and immune surveillance183. In fact, MMPs secreted 
by peritumoural adipose depots have already been described to promote tumour cell 
invasive capabilities148. To functionally characterize the different adipose depots, gelatin 
zymography studies were performed to assess MMPs activity on the supernatants of PrAT 
and ScAT ex vivo explant cultures (Figure 15).  
 
Figure 15 | MMP2 and MMP9 proteolytic activity in perirenal- and subcutaneous-derived conditioned media. (A) 
Conditioned media (CM) collected from the ex vivo culture of perirenal and subcutaneous adipose tissue were run on gelatin 
zymograms. Total protein of the different CMs was quantified and the same amount of protein was loaded. Proteolytic activity 
was revealed as white bands on a dark background stained with Coomassie. (B) Densitometry analysis of paired adipose 
depots derived from 5 different patients, as given by the optical density (OD) per mm2, was performed using Quantity One 
(Bio-Rad). Data are represented as mean ± SD. **p < 0.01 as determined by paired two-tailed Student’s t test. 
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Overall, Figure 15A depicts an increased activity of MMP2 (both pro and active 
forms) and pro-MMP9 in PrAT-derived conditioned media (CM) relative to ScAT-derived 
CM. In fact, data obtained from the densitometry analysis of the proteolytic activity of both 
AT-derived supernatants revealed a significant increase in the activity of the all set of MMPs 
analysed in the perirenal depot in regard to subcutaneous adipose tissue (Figure 15B). 
 
 
Collectively, these data indicate that, in fact, intrinsic differences between perirenal 
and subcutaneous adipose depots exist. In summary, perirenal displays smaller adipocytes, 
exhibits increased expression of thermogenic-related genes and enhanced secretion of 
matrix metalloproteinases, evidencing that site-specific differences may contribute 
differently to clear cell renal cell carcinoma. 
 
ADIPOSE TISSUE AND CLEAR CELL RENAL CELL CARCINOMA 
CROSSTALK 
Obesity has been largely associated with the incidence of clear cell renal cell 
carcinoma, underlying a clear effect of the hypertrophic adipose depots to cancer promotion 
and progression. To better understand the influence of different adipose depots in cancer 
development, 786-O and Caki-1 cell lines cultured under the influence of PrAT- or ScAT-
derived CM of paired patients were used. An initial approach focused on a comprehensive 
analysis on the cellular-specific gene expression modifications and, at a later stage, cells 
were submitted to functional analyses in order to understand if changes in the gene 
expression profile of these cells translated into a physiological mechanism. 
 
Adipose Tissue Alters the Gene Expression Profile of 786-O Cells 
Following ex vivo explant culture of perirenal and subcutaneous adipose tissue 
explants, the resulting supernatants were collected, and 786-O cells were cultured with or 
without (control, CTRL) the influence of these conditioned media. To examine whether 
soluble factors secreted by the different adipose depots alter 786-O gene expression, RNA 
extracted from cells stimulated or non-stimulated with AT supernatants was used to assess 
relative expression levels of genes associated with tumour-promoting processes (Figure 
16). 
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Figure 16 | Adipose tissue-derived conditioned media induces alterations in mRNA relative expression of hypoxia-, 
inflammatory- (A), EMT- (B) and stem- (C) related genes in 786-O cells. RNA extracted from 786-O cells cultured under 
the influence of perirenal and subcutaneous adipose tissue or cultured under normal conditions (CTRL) was reverse 
transcribed and relative mRNA levels were obtained by quantitative real-time PCR (n=5). Relative gene expression was 
normalized to Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) mRNA levels. Bars represent mean values and error 
bars represent standard deviation (SD). *p < 0.05 and **p<0.01 as determined by One-way ANOVA with Tukey’s multiple 
comparisons test. 
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Increased levels of hypoxia and inflammatory associated genes could be found in 
cells cultured under the influence of both adipose depots’ supernatants when compared to 
unstimulated cells (Figure 16A). In particular, 786-O cells cultured with PrAT-derived CM 
significantly increased the expression of hypoxia inducible factors (HIF1α and HIF2α). In 
turn, ScAT secreted factors mainly increased HIF2α and IL6 expression in these cells 
(Figure 16A). No major differences were noticed in regard to TGFβ1 relative expression. 
When assessing the expression of major epithelial to mesenchymal transition 
transcription factors (EMT-TFs), an overall increase of the mRNA relative expression could 
be seen in 786-O cells cultured under the influence of both AT-derived CM when compared 
with control counterparts. Notably, perirenal and subcutaneous secreted factors 
significantly increased SLUG levels (Figure 16B). 
Once EMT is described to induce cancer stemness in different models, the analysis 
of two stem-related genes in ccRCC was performed (Figure 16C). OCT4 mRNA relative 
expression was increased in 786-O cells stimulated with soluble factors derived from 
perirenal and subcutaneous adipose tissue ex vivo culture when compared to control. 
However, NANOG only increased its levels whenever 786-O cells were cultured under the 
influence of ScAT-derived CM. 
Altogether, PrAT and ScAT secreted factors influenced 786-O gene expression 
profile. 
 
Adipose Tissue Soluble Factors Have No Effect on Caki-1 Cells 
Gene Expression  
A similar approach to the one used in the previous chapter was used in Caki-1 cells. 
Caki-1 under the influence of AT-derived soluble factors revealed no significant differences 
in mRNA expression levels of tumour-promoting genes (Figure 17).  
Figures 17A and B showed similar levels of mRNA expression for both genes 
involved in ccRCC developing process and EMT-TFs. However, even though a statistically 
significative difference could not be found, a slight increase in genes encoding stem-like 
markers in ccRCC could be observed (Figure 17C), suggesting a possible role for AT 
systemic factors in ccRCC stemness. 
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Figure 17 | Adipose tissue-derived conditioned media does not appear to impact mRNA relative expression of tumour 
promoting- (A), EMT- (B) and stem- (C) related genes in Caki-1 cells. RNA extracted from Caki-1 cells cultured under the 
influence of perirenal and subcutaneous adipose tissue or cultured under normal conditions (CTRL) was reverse transcribed 
and relative mRNA levels were obtained by quantitative real-time PCR (n=5). Relative gene expression was normalized to 
Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) mRNA levels. Bars represent mean values and error bars represent 
standard deviation (SD). Statistics determined by One-way ANOVA with Tukey’s multiple comparisons test. 
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Adipose Tissue-Derived CM Inhibits Cell Proliferation of 786-O 
Cells  
Following gene expression analysis, 786-O and Caki-1 cells cultured under the 
influence of PrAT or ScAT supernatants or under normal conditions were functionally 
characterized. Initially, the proliferating rates of both cell lines were determined resorting to 
the thymidine analog EdU (Figure 18). Both PrAT- and ScAT-derived CM impaired 786-O 
proliferation rates when compared to control (Figure 18A and B). In fact, 786-O actively 
proliferating cells were reduced in approximately 15% when cultured with both AT-derived 
CM in comparison to control (Figure 18B). In turn, no influence could be seen regarding 
the stimulation of Caki-1 with PrAT- and ScAT-derived CM (Figure 18C and D) in all three 
conditions. 
Importantly, an overall effect of PrAT- and ScAT-derived CM in 786-O cells could be 
noticed, impairing its growth in vitro, underlying a role of these adipose depots to localized 
primary ccRCC tumours. 
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Figure 18 | Proliferation rates of 786-O and Caki-1 cell lines. Proliferative rates of 786-O and Caki-1 cells cultured under 
the influence of PrAT- or ScAT-derived CM or under normal conditions (CTRL) was assessed resorting to an EdU positive 
incorporation assay. EdU is a thymidine analog that is incorporated into newly synthesized DNA, allowing the measurement 
of cell proliferation. (A) Representative histograms of unstained and Edu+ cells in 786-O cells. (B) Actively proliferating 786-O 
cells cultured with and without adipose-derived CM (n=5). (C) Representative histograms of unstained and Edu+ cells in Caki-
1 cells. (D) Actively proliferating Caki-1 cells cultured with and without adipose-derived CM (n=5). Bars represent mean values 
and error bars represent standard deviation (SD). ****p < 0.0001 as determined by One-way ANOVA with Tukey’s multiple 
comparisons test. 
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Adipose Tissue Derived CM Promotes 786-O Apoptosis 
Evasion of apoptosis is a well-established hallmark of cancer. In order to investigate 
the role of PrAT and ScAT-derived soluble factors on this mechanism, 786-O and Caki-1 
cells cultured under the influence of perirenal or subcutaneous CM or under normal 
conditions were analysed by flow cytometry, following staining with annexin V and 
propidium iodide (Figure 19). This staining precedes the loss of membrane integrity and 
allows the distinction between live, apoptotic and necrotic cells.  
 
 
Figure 19 | Effect of perirenal and subcutaneous adipose tissue-derived conditioned media on the cell apoptosis of 
786-O (A) and Caki-1 cells (B). Apoptosis was measured as the incorporation of annexin V and propidium iodide (PI) in 786-
O (A) or Caki-1 (B) cells. Cells cultured under the influence of PrAT- or ScAT-derived CM or under normal conditions (CTRL) 
were stained with annexin V and PI. Representative dot plots of live (annexin-PI- cells), early-apoptotic (annexin+PI-) and late-
apoptotic/necrotic (annexin+PI+) cells are depicted in (A) for 786-O cells (n=5) and (B) for Caki-1 cells (n=5). (C and D) 
Representative graph bars for the rate of live, early-apoptotic, and late-apoptotic cells in 786-O cells (C) and Caki-1 cells (D). 
**p < 0.01 and ***p < 0.0001 as determined by One-way ANOVA with Tukey’s multiple comparisons test. 
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Soluble factors from PrAT ex vivo culture increased the percentage of both 786-O 
early apoptotic and late apoptotic/necrotic cells when compared to control (Figure 19A). 
This effect was even bigger when 786-O cells were cultured under the influence of ScAT-
derived secreted mediators (Figure 19A). In fact, the subcutaneous adipose influence over 
786-O cells surpassed the one exhibited by both PrAT and or control conditions (Figure 
19C). Caki-1 cells decreased the number of live cells when stimulated with PrAT-derived 
CM when compared to control. However, no major differences could be seen between 
stimulated and control cells relatively to the number of cells that undergo apoptosis. (Figure 
19B and D).  
 Overall, subcutaneous adipose tissue secreted factors appeared to promote 786-O 
cells apoptotic processes. This effect was less pronounced when cells were cultured under 
the influence of perirenal-derived CM. These data suggest that the subcutaneous depot can 
have a systemic effect on ccRCC primary tumours modulating apoptotic processes. 
Moreover, and even though PrAT did not possess such a conclusive effect in 786-O cells, 
the results also suggest that the adjacent perirenal adipose depot may play a role in the 
apoptotic behaviour of ccRCC primary tumours. 
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DISCUSSION 
 
Altered microenvironment within a tissue is thought to provide permissive signals for 
tumour development. Importantly, adipocyte-secreted leptin was found to be upregulated in 
obese patients and different studies have suggested a role for leptin as a tumour growth 
promoter184,185, by inducing STAT3 signalling186, and consequently promoting proliferation 
and angiogenic differentiation of leptin receptor-expressing endothelial cells187,188. 
Contrarily, in the obese state, downregulated adiponectin secretion impairs its role on 
inhibiting tumour growth through the binding and sequestration of growth factors172. In 
addition, adiponectin reduced tumourigenesis in several in vivo studies189,190 and its 
deficiency promoted tumour growth191. Furthermore, the production of pro-inflammatory 
adipokines, importantly, IL-6, has been shown to promote tumour growth in different types 
of cancer192,193. Adipocyte-derived IL-6 has been shown to induce an EMT phenotype in 
breast cancer cells via STAT3 signalling194. However, the antitumour effect of IL-6 blocking 
was only observed in high fat diet-induced mice, but not in controls, suggesting that the 
inflammatory state during obese conditions can influence the tumour outcome195. 
Additionally, adipocytes can modify the immune microenvironment by recruiting pro-
inflammatory macrophages through the CCL2/IL-1β/CXCL12 axis, creating a permissive 
niche for cancer initiation143. All these findings support the interest on adipocytes and cancer 
crosstalk, which can be crucial for the prevention and treatment of obesity-associated 
cancers. Tumours developing within this favorable niche eventually progress towards 
aggressive, metastatic phenotypes196. Given the upsurge of the prevalence of obesity 
worldwide to pandemic levels, the disclosure of the mechanisms underlying the association 
between obesity and different types of cancer is urgently needed. In fact, a growing body of 
epidemiological data has made clear the association between obesity and increased cancer 
risk106,107,197. Particularly, compelling evidence linking obesity with renal cell carcinoma has 
been reported106,198-200. Adipocyte hypertrophic growth disrupts the dynamic role of the 
adipose tissue in energy homeostasis, consecutively leading to inflammation, modifications 
of adipokine signalling, lipid deregulation and shedding of mesenchymal-like cells from 
adipose depots to tumour niches. The plethora of abnormal processes that occur during 
obesity fosters cancer development and progression164. However, even though excess body 
adiposity is directly associated with increased risk for RCC development, obese patients at 
diagnosis experience longer survival than non-obese patients, a phenomenon designated 
“obesity paradox”201. To address this matter, a better understanding of the mechanistic 
processes that link adipose tissue to RCC progression is required. 
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This thesis sought to provide a study over the influence of different adipose depots 
on clear cell renal cell carcinoma (ccRCC), particularly the perirenal at the vicinity of RCC 
and subcutaneous adipose tissue, by addressing their role on ccRCC cell lines. Even 
though tumours are highly complex 3D structures, cell-line based research has contributed 
to a plethora of discoveries and, importantly, to the development of cancer therapies and 
effective drugs that were later on introduced into practice202. In line with this, two different 
ccRCC cell lines were used for the development of this work. To understand if differences 
between site-specific adipose depots and distinct ccRCC genetic profiles and tumour 
progression exist, 786-O and Caki-1 RCC lines were used. Whereas 786-O cells are 
defective in VHL expression and mimic ccRCC primary tumours, the Caki-1 RCC line is a 
model of distant metastatic ccRCC harboring wild-type VHL203. This allowed mimicking in 
vitro the influence of distant or tumour adjacent adipose depots in metastatic or localized 
ccRCC. 
Importantly, a thorough characterization of the different adipose depots can 
contribute to a better understanding of the adipose tissue potential for cancer interactions. 
In this regard, both adipose depots were characterized with the employment of 
morphological, genetic and functional approaches. Preliminary results indicated that the 
perirenal adipose tissue (PrAT) presented decreased adipocyte size, as opposed to 
subcutaneous adipose tissue (ScAT). In fact, a reduction on the adipocyte area is consistent 
with the fact that adipocytes that exhibit a brown-like phenotype decrease size due to its 
lipolytic and thermogenic roles204. Additionally, gene expression profiling of the different 
adipose depots revealed a higher expression of thermogenic-related genes (including 
UCP1, EVA1 and TMEM26) on PrAT when compared to ScAT. Importantly, even though 
no statistically significant difference could be found, the overall UCP1 mRNA levels in PrAT 
were over 20-fold the expression of the same marker in ScAT. These data are in line with 
a number of reports that argue that the perirenal adipose tissue is a brown adipose 
depot60,205-207. Counterintuitively, even though PrAT displays higher relative expression 
levels of genes involved in brown phenotypic traits, SLC7A10 levels, a white adipocyte-
specific cell surface protein, increased in the perirenal depot relatively to subcutaneous 
adipose tissue, as well. Defining adipose depots according to white, beige and brown 
composition is particularly difficult in humans since most tissues present heterogeneous 
populations of adipocytes63. In accordance, the relative gene expression levels observed 
for the perirenal depot might be the result of an intra-depot heterogeneity. In fact, a recent 
report portrayed the existence of dormant BAT within the perirenal depot that could be 
reactivated upon external stimuli. In concordance with the data presented here, the authors 
claim that similarly to subcutaneous WAT, dormant perirenal BAT was also characterized 
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by a unilocular morphology and identical gene expression profile in regard to ScAT208. 
Overall, here, we present evidences supporting that the perirenal adipocyte repertoire 
exhibit a BAT-like phenotype in contrast to subcutaneous WAT. 
Following ex vivo culture of adipose tissue explants and respective conditioned 
media (CM) collection, a first approach to unravel the functional role of these tissues 
focused on the proteolytic activity that these depots possess. Matrix metalloproteinases 
(MMPs) are enzymes with proteolytic capabilities critical for the remodelling of the 
extracellular matrix (ECM) that have been associated with invasive and metastatic tumour 
behaviour. MMPs are secreted by both stroma and cancer cells and mediate several 
processes, including growth, apoptosis, migration and invasion of cancer cells, as well as 
regulation of tumour angiogenesis and immune tolerance183,209,210. Peritumoural adipose 
depots have already been described to promote invasive properties of tumour cells, directly 
by the production of multiple MMPs or through chemotactic agents148,211. The proteolytic 
activity of MMP2 and MMP9 was increased in the perirenal in opposite to subcutaneous 
depots, underlying a hypothetic effect of the tumour on the adjacent adipose tissue and 
remaining stroma to increase the levels of proteolytic enzymes to promote tumour invasion 
and/or metastasis. Further data is required to substantiate this premise. 
At this point, the scope of this thesis shifted towards a better understanding of the 
influence that soluble factors secreted by two distinct anatomical fat depots had on ccRCC 
development and progression. Functional analyses of 786-O and Caki-1 RCC lines cultured 
under the influence of both PrAT- or ScAT-derived supernatants were conducted. These 
focused on the proliferative and apoptotic characteristics of these cells. In fact, the hind 
referred processes are established hallmarks of cancer12. 786-O cells displayed decreased 
proliferative rates and increased cell death when compared to control. Most studies report 
a protumourigenic role for the adipose tissue. Adipocyte-related cancer progression is 
thought to occur through proliferative and anti-apoptotic processes that promote 
malignancy. Concomitantly, the adipokine repertoire has a critical impact on cancer cell 
traits. In fact, adipocyte secreted factors, including leptin, IL-6, TNF-α and VEGF have 
angiogenic and proliferative effects over the growing tumour mass113,196,212. Furthermore, 
cancer-associated adipocytes undergo lipolysis that serves as a source of energy for cancer 
cells, promoting tumour growth213. In contrast, a tendency to decrease actively proliferating 
cells when 786-O RCC line is cultured under the influence of both analysed depots in 
comparison to unstimulated cells could be seen. Concordantly, these cells also displayed 
higher apoptotic rates than cells cultured under normal conditions. These results suggest a 
role for adipose tissue in tumour mass regression, giving some insight over the obesity 
paradox that is seen in RCC patients. Importantly, the inflammatory signals released from 
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the adipose tissue, that are exacerbated upon obesity, might be the underlying cause for 
the recruitment of immune populations, inducing the production of reactive oxygen species 
and consequent genotoxic stress124,126. To limit genomic instability, cells are equipped with 
DNA damage response elements and DNA repair proteins that contribute to the repair and 
tolerance of DNA lesions. Dysregulated repair mechanisms and the underlying genotoxic 
stress promote pathways of apoptotic and cell death, that are ultimately controlled by a 
threshold between pro-survival and pro-apoptotic factors214-216. Moreover, adipose-derived 
stem cells (ASCs) were shown to inhibit prostate cancer cell proliferation and induce 
apoptosis, in accordance to the data presented here217. These effects might be related to 
the action of adiponectin on proliferation and apoptotic processes, once this adipokine is 
reported to increase apoptotic signalling and reduce proliferation in cancer progression218. 
The combined evidence might suggest that adiponectin or the stromal compartment of the 
different adipose depots might constitute crucial players in cancer regression. However, the 
exact molecular mechanisms through which the adipose soluble factors contribute to these 
mechanisms are unknown, and further analysis is required. 
Given the absence of VHL in 786-O cells, these cells already express high amounts 
of hypoxia inducible factors (HIF). However, upon exposure of these cells to AT-derived 
conditioned medium from both perirenal and subcutaneous depots, the mRNA levels of 
these transcription factors are further increased. Moreover, the gene expression levels of 
pro-inflammatory (IL6), EMT-associated (SLUG) and stem-related genes (OCT4) are 
increased in 786-O cells cultured under the influence of adipose depots supernatants. 
These data oppose to some extent the results obtained from the functional analysis 
performed on the same cells. This indicates that, even though 786-O cells are increasing 
its apoptotic rates and decreasing its proliferative capability, the surviving cells acquire a 
more aggressive phenotype somehow. Even though the hypothetic genotoxic stress 
decreases 786-O viability, the cells that are capable to survive seem to acquire a more 
aggressive phenotype, concomitant with the increased expression of both EMT-TFs and 
stemness-related markers. An emerging hypothesis relies on the possibility that the adipose 
tissue might increase the senescent cell burden in the developing tumour. Cell senescence 
denotes a durable form of cell-cycle arrest caused by multiple stress-related processes, 
including telomere dysfunction, genotoxic stress, inflammation and metabolic 
dysregulation219. Tumour cells that are induced into a state of senescence throughout 
chemotherapeutic or radiation approaches have been reported to recover self-renewal 
capacity and increase cancer aggressiveness220.  In fact, a population of pseudo-dormant 
cells that evade the cytotoxic impact that adipose tissue-derived soluble factors might have 
on 786-O cells, might resurge with a more aggressive phenotype. Notably, these cells are 
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thought to increase the population of cancer stem cells, being the underlying cause for 
therapy resistance and disease recurrence221. Overall, both PrAT- and ScAT-derived 
supernatants increase the expression of different genes that influence tumour progression 
and development through a hypothetic selective process, whereby cells that survive the 
initial genotoxic effects of adipose tissue prosper within the established microenvironment 
and drive tumour growth, invasion and metastatic behaviour. Obviously, the conclusions 
drawn from this work relative to the influence of different adipose depots on ccRCC primary 
tumours remain to be proven and will be the focus of future work. 
In regard to Caki-1 cells, the increased metastatic potential of these cell line, and 
the intrinsic phenotypic aggressiveness it displays, hampered the effects of AT-derived CM. 
Moreover, it is somehow expected that adjacent tumour adipose tissue might have a direct 
influence on cancer cells phenotypic changes, particularly, when the evading tumour mass 
reaches the adipose organ. However, in 786-O cells an effect of nearby and distant adipose 
tissue soluble factors could be seen implying paracrine and systemic influences over the 
localized ccRCC cell line. In turn, Caki-1 cells, which derive from a metastatic site, do not 
respond to both AT secreted factors influence. Overall, it seems that adipose tissue might 
promote tumour aggressiveness in a site-specific manner.  
It is important to notice that, several methodological approaches and/or sample 
collection deficits might influence the different effects seen in both cell lines, and 
importantly, the absence of effects detected in Caki-1 cells cultured under the influence of 
AT supernatants. Incubation periods, seeding densities and the stratification of patients 
according to clinical and pathological data might be critical to increase the importance of 
this study for the clinical practice. In fact, the limiting number of samples collected (due to 
temporal restriction) is a critical factor that hindered this work. In conclusion, this study sets 
some evidence over the influence of different adipose depots on renal cell carcinoma 
progression and aims at providing data to conduct future insights in the adipose tissue/RCC 
interface, including the development of new therapeutic approaches that target both 
adjacent and/or distant adipose tissue as well as the tumour itself. 
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CONCLUDING REMARKS AND FUTURE 
PERSPECTIVES  
  
 Tumours largely depend on their tumour microenvironment for sustained growth, 
invasion and metastasis. Targeting the tumour microenvironment non-transformed cells 
represents an attractive therapeutic strategy. Adipocytes have been a neglected component 
of this landscape. However, in recent years, increased interest has been laid upon the role 
of this cell type to tumour initiation and progression. In fact, several studies have disclosed 
a robust association between obesity and increased risk to develop several types of cancer, 
making the concept of obesity indissociable from cancer. Importantly, renal cell carcinoma 
is among the cancers that are highly associated with obesity. Disclosing the role of adipose 
tissue towards RCC progression is thus of crucial importance. Even though multiple factors 
could explain the increased incidence of RCC in obesity, including dysfunctional adipokine 
signalling, increased leptin and lipids, decreased adiponectin and inflammatory signalling, 
the mechanistic processes behind these are largely unknown. The work herein developed 
reflects the influence that both the perirenal and the subcutaneous adipose depots might 
have for RCC carcinogenic processes and sets its basis on the development of future work 
that aims to disclose the mechanistic insights behind these processes, and the discovery 
and development of novel therapeutics. 
 Future work following on this thesis will seek to unveil the precise mechanisms 
through which the adipose depot influences renal cell carcinoma, with a focus on 
immunometabolic and cellular energetics processes, as well as in the related signalling 
pathways. In line with this, three main objectives should be pursued: 
1. To unravel the role of secreted factors to RCC growth. Establishing the 
differences of site-specific adipose adipokine repertoire, emphasizing the 
immunomodulatory role of these secreted factors. 
2. To unveil the distinct immune populations that are part of the adipose 
landscape of both peritumoural and distant adipose depots that may 
ultimately contribute towards disease. 
3. To establish the influence of the metabolic symbiosis phenomenon on 
RCC and unravel the role of lipid metabolism to tumour cell growth. 
A better understanding of these mechanisms and concurrent influence on cancer 
progression should pave the way to increase the knowledge over the influence of the 
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adipose tissue over RCC and to develop new therapeutic approaches that target not only 
cancer cells, but the adipose landscape. 
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